Kiromic says Deltacel-01 trial patient reaches progression-free survival

Kiromic BioPharma (KRBP) reported continued efficacy results from the 10-month follow-up visit for the fourth patient enrolled in its Deltacel-01 Phase 1 clinical trial and provides an enrollment update. This trial is evaluating Deltacel, the company’s allogeneic, off-the-shelf, Gamma Delta T-cell therapy, in patients with stage 4 metastatic or locally-advanced non-small cell lung cancer who have failed to respond to standard therapies. The fourth patient in Deltacel-01 demonstrated a partial response at the eight-month follow-up visit and continued without any evidence of disease progression as of the 10-month follow-up visit, thereby extending progression-free survival to 10 months. Additionally, Kiromic reports that two subjects are undergoing screening and are scheduled to start treatment at Texas Oncology in Tyler, Texas, in late February and early March, respectively.